VCBeat Health Contact Us
Home Former Stryker Executive Erik Todd Appointed CEO of Swan EndoSurgical Ahead of IPO

Former Stryker Executive Erik Todd Appointed CEO of Swan EndoSurgical Ahead of IPO

Dec 03, 2025 19:04 CST Updated 19:04
Stryker

Medical Device R&D, Production, and Sales Company

Johnson & Johnson

Medical Device R&D and Manufacturer

Author | Yueqing
Source | CPhI China Medical Devices

Giant Companies Are Placing Bets on Surgical Robots: The Battle Between Foreign and Chinese-Made Intensifies.

01

Former Stryker Executive
Join an Olympus subsidiary

December 2,OlympusStryker Official Website Announcement:Stryker's robotics technology company, Swan EndoSurgical, appoints Erik Todd as the newChief Executive Officer。
Image
In joining SwanPreviously,Todd inStryker works for more than25Year,Serve asRobotics and Empowerment Technology DepartmentDoorVice President and General Manager，In expansionNext-Generation Robotic Platforms, Minimally Invasive Surgery, and Digital/AI-Empowered Technologies...and other fields have rich experience in innovation.
Swan EndoSurgicalIs oneA home startup company,Focus on developing a fully integrated, flexible endoluminal robotic platform,In July this yearByOlympus andRevival Healthcare CapitalCo-founded.
A third type of surgical platform that is distinct from traditional laparoscopic robots and electronic endoscopes,IntracavitaryThe robot is based onRobotic arm and flexible navigation system,InPerforming high-precision surgical operations inside natural cavities。
Unlike the conventional approach of mergers and acquisitions + integration in the past, the two medical giants chose“Build-to-Buy”The cooperation model. According to public information, this collaboration advances through a "phased progress + option acquisition" approach.Initial InvestmentFor $65 million, the total investment amountUp to 458 million US dollars。

New President of OlympusBob White said in an interview that,ThisIncubate First, Then AcquireThis model is absolutely the future direction. Innovation within large companies often faces greater resistance, while external incubation can both contribute core advantages and maintain the flexibility of start-up enterprises.

As the global leader in endoscopy, Olympus heavily invests in intracavitary solutions.Robots, which are seen as a natural decision within the industry. From the disclosed information,Swan focused his gaze onComplex gastrointestinal interventional treatment, a field that remains unexplored.。

In November this year, Olympus announced a future-oriented global strategic transformation plan, explicitly proposing to focus on the integrated application of artificial intelligence, robotics, and digital healthcare ecosystems.
As can be seen from Todd's resume,Olympus' Future Strategy Highly Aligned, Along with New Leader Taking OfficeSwan's preliminary preparations have been nearing completion, and the chain from clinical to commercial to development has become increasingly clear.

02

Surgical Robot Market Booms

Giant Competition in Multiple Segmented Markets


As the technological pinnacle in the field of surgical treatment, the surgical robot market has continued to expand in recent years, gradually becoming a battleground for medical device giants.
Intracavitary robots are regarded asAn important direction for the next generation of surgical robots,But at present, most of them are still in the preclinical research or early clinical trial stage, except forSwanExternally,Johnson & Johnson,Surgical AutomationsOthers are also exploring in this field.
In the current surgical robot market, traditional endoscopic robots remain the largest细分 track. According to statistics from Guoyuan Securities, the global market size for endoscopic surgical robots continues to grow.It is expected to reach 28.6 billion US dollars in 2030。
Da VinciYesThe absolute leader in the field of endoscopic robotics,Global installations exceed 10,000 units, with over 2.68 million surgeries completed cumulatively in 2024.Medtronic, Johnson & Johnson、CMR SurgicalForeign giants have followed suit in recent years, forming a challenge to da Vinci and capturing market share in niche segments.
Driven by the improvement in diagnostic and treatment capabilities and national policy incentives, the endoscopic robot market is showing vigorous growth. According to statistics from MedEquipData,In 2024, the sales volume of domestically produced laparoscopic surgical robots in China exceeded 100 units, with a year-on-year growth rate of 108.51%., sales volume doubled compared to 2023.
202The market has been continuously hot for 5 years, according toAccording to statistics from Zhongcheng Data, in the first quarter of this year, surgical robot...New installations increased by up to 130% year-on-year, with an expected growth of over 20% for the whole year of 2025.。
In the context of a rapidly expanding market, the localization process has also significantly accelerated, with the localization rate of domestic endoscopic surgical robots in 2024 increasing compared to previous years.Increased by 16.28 percentage points compared to the same period last year., which is close to the level of imported brands.
Among the domestically produced representatives,MicroPort,Toumai,Surui,CondoHave already gained a firm foothold，With localized supply chainThe cost advantage continues to increase, and the path to overseas market expansion has already begun. WithTaking Tumai as an example, in the first half of 2025, it secured 18 orders in overseas markets and completed the commercial installation and sales of 16 units.
At the same time, new players are still entering the market.According toAccording to statistics from Zhongcheng Data, as of the second quarter of 2025,This year, a total of 5 laparoscopic surgical robots have entered the market.。
2024Product ApprovalConorth, and recently completed a newAn oversubscribed financing round of approximately US$200 million,The first commercialized unit has officially landed.
MindrayAlso officially announced this year to enter the fieldEndoscopic Robot Track, ItsInvestor relations records were expressed in a high-profile manner,There is a gap between the existing domestically produced laparoscopic surgical robots and the da Vinci surgical robot.Mindray Enters the Surgical Robot Market with Chain Advantages, Aiming to Become a World-Class Surgical Robot。
In this blue ocean marketIn the field, the competition between veteran giants and rising newcomers is becoming increasingly fierce. Based on high technological barriers and massive R&D investment, there are hardly any weak participants in the track of endoscopic robotics.The market competition has already begun.

END

Content Communication: WeChat nrzx0321
Image